Hisakazu Matsumoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hisakazu Matsumoto has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Mamoru Takenaka
Department of Gastroenterology and Hepatology Faculty of Medicine Kindai University Osaka Japan
3 shared publications - Akira Kurita
Department of Gastroenterology and Hepatology, Rakuwakai Otowa Hospital, Kyoto, Japan
2 shared publications - Hirofumi Kawamoto
Department of General Internal Medicine 2, Kawasaki Medical School, Okayama, Japan
2 shared publications - Hiroko Nebiki
Department of Gastroenterology, Osaka City General Hospital, Osaka, Japan
2 shared publications - Kazuya Matsumoto
Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Nishi-cho 36-1, Yonago 683-8504, Japan
2 shared publications - Koichi Fujita
Department of Gastroenterology and Hepatology, Yodogawa Christian Hospital, Osaka, Japan
2 shared publications
Latest Publications
- Open Access
- 1 March 2023
- Published by Wolters Kluwer Health in Endoscopic Ultrasound
- Vol. 12 (2) , 298-299
EUS-guided hepaticogastrostomy of a difficult-to-access biliary obstruction involving the caudate lobe (with video)
- 1 March 2023
- Published by Wolters Kluwer Health in Endoscopic Ultrasound
- Vol. 12 (2) , 298-299
Open AccessEUS-guided hepaticogastrostomy of a difficult-to-access biliary obstruction involving the caudate lobe (with video)
- Open Access
- 4 February 2022
- Published by Wiley in Digestive Endoscopy
- Vol. 34 (6) , 1198-1204
Multicenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post‐endoscopic retrograde cholangiopancreatography pancreatitis
Objectives: The reported incidence of adverse events (AEs) in endoscopic retrograde cholangiopancreatography (ERCP) varies between 2.5% and 14%. The aim of this study was to evaluate the incidence and severity of AEs in biliary ERCP and to specify the risk factors and preventive measures for post‐ERCP pancreatitis (PEP).Methods: Patients with biliary disease with intact papilla were prospectively enrolled at 36 hospitals between April 2017 and March 2018. The primary outcomes were the incidence and severity of AEs.Results: A total of 16,032 ERCP procedures were performed at the 36 hospitals during the study period and 3739 patients were enrolled. The overall incidence of AEs was 10.1% and ERCP‐related mortality was 0.08%. PEP developed in 258 cases (6.9%), bleeding in 33 (0.9%), instrumental AEs in 17 (0.5%), infections in 37 (1.0%), cardiovascular AEs in eight (0.2%), pulmonary AEs in eight (0.2%), drug reaction AE in one (0.03%), pain in 15 (0.4%), and other AEs in 15 (0.4%). Multivariable analysis showed significant risk factors for PEP were: female of younger age, pancreatic guidewire‐assisted biliary cannulation, temporary guidewire insertion into the pancreatic duct, total procedure time >60 min, and post‐ERCP administration of non‐steroidal anti‐inflammatory drugs. Effective preventive measures were prophylactic pancreatic stenting (PPS) and epinephrine spraying onto the papilla.Conclusions: In patients with intact papilla who underwent biliary ERCP, the incidence of AEs was 10.1% and the mortality was 0.08%. PPS and epinephrine spraying may prevent PEP.Registration: This study was registered in the University Hospital Medical Information Network (UMIN000024820).
- 4 February 2022
- Published by Wiley in Digestive Endoscopy
- Vol. 34 (6) , 1198-1204
Open AccessMulticenter prospective cohort study of adverse events associated with biliary endoscopic retrograde cholangiopancreatography: Incidence of adverse events and preventive measures for post‐endoscopic retrograde cholangiopancreatography pancreatitis
Objectives: The reported incidence of adverse events (AEs) in endoscopic retrograde cholangiopancreatography (ERCP) varies between 2.5% and 14%. The aim of this study was to evaluate the incidence and severity of AEs in biliary ERCP and to specify the risk factors and preventive measures for post‐ERCP pancreatitis (PEP).Methods: Patients with biliary disease with intact papilla were prospectively enrolled at 36 hospitals between April 2017 and March 2018. The primary outcomes were the incidence and severity of AEs.Results: A total of 16,032 ERCP procedures were performed at the 36 hospitals during the study period and 3739 patients were enrolled. The overall incidence of AEs was 10.1% and ERCP‐related mortality was 0.08%. PEP developed in 258 cases (6.9%), bleeding in 33 (0.9%), instrumental AEs in 17 (0.5%), infections in 37 (1.0%), cardiovascular AEs in eight (0.2%), pulmonary AEs in eight (0.2%), drug reaction AE in one (0.03%), pain in 15 (0.4%), and other AEs in 15 (0.4%). Multivariable analysis showed significant risk factors for PEP were: female of younger age, pancreatic guidewire‐assisted biliary cannulation, temporary guidewire insertion into the pancreatic duct, total procedure time >60 min, and post‐ERCP administration of non‐steroidal anti‐inflammatory drugs. Effective preventive measures were prophylactic pancreatic stenting (PPS) and epinephrine spraying onto the papilla.Conclusions: In patients with intact papilla who underwent biliary ERCP, the incidence of AEs was 10.1% and the mortality was 0.08%. PPS and epinephrine spraying may prevent PEP.Registration: This study was registered in the University Hospital Medical Information Network (UMIN000024820).
- Open Access
- 1 June 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 91 (6) , AB104
1173 A MULTICENTER PROSPECTIVE COHORT STUDY OF ADVERSE EVENTS ASSOCIATED WITH BILIARY ERCP
- 1 June 2020
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 91 (6) , AB104
Open Access1173 A MULTICENTER PROSPECTIVE COHORT STUDY OF ADVERSE EVENTS ASSOCIATED WITH BILIARY ERCP
- 22 April 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (10) , 2982-2991
Comparison of the Diagnostic Performance of Newly Designed 21-Gauge and Standard 22-Gauge Aspiration Needles in Patients with Solid Pancreatic Masses
Although endoscopic ultrasound-guided fine needle aspiration (EUS–FNA) has been widely used for the diagnosis of pancreatic tumors, the ability to obtain adequate pancreatic tumor tissue needs to be improved.
- 22 April 2019
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 64 (10) , 2982-2991
Comparison of the Diagnostic Performance of Newly Designed 21-Gauge and Standard 22-Gauge Aspiration Needles in Patients with Solid Pancreatic Masses
Although endoscopic ultrasound-guided fine needle aspiration (EUS–FNA) has been widely used for the diagnosis of pancreatic tumors, the ability to obtain adequate pancreatic tumor tissue needs to be improved.